Sort   by:  
 Page size 
GenomicsRNA-seq of human NSCLCL treated with Alectinib, Lorlatinib or Brigatinib
RNA-seq of human NSCLCL treated with Alectinib, Lorlatinib or Brigatinib
PRJEB50324 | ENA
TranscriptomicsRNA-seq of human NSCLCL treated with Alectinib, Lorlatinib or Brigatinib
To better understand the differences between different ALK inhibitors on ALK positive NSCL cell lines, we performed RNA-seq analysis on samples treated with 3 types of ALK inhibitors: Alectinib, Lorlatinib and Brigatinib
ORGANISM(S): Homo sapiens 
2022-07-26 | E-MTAB-11342 | biostudies-arrayexpress
UnknownCentral location and risk of imaging occult mediastinal lymph node involvement in cN0T2-4 non-small cell lung cancer.
Not available
S-EPMC7797819 | biostudies-literature
ProteomicsALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expression
Anaplastic lymphoma kinase (ALK) fusion variants in non-small-cell-lung cancer (NSCLC) consist of numerous dimerising fusion partners, with the most common being EML4. Clinical data suggests that the degree of treatment benefit in response to ALK tyrosine kinase inhibitors (TKIs) differs among the v...
ORGANISM(S): Homo sapiens (Human) 
2023-02-16 | PXD035100 | Pride
Human Nsclcl Orbitrap fusion lumos 
Sort   by:  
 Page size